Northwest Biotherapeutics (NWBO) : Traders are bullish on Northwest Biotherapeutics (NWBO) as it has outperformed the S&P 500 by a wide margin of 60.4% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.73%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.9% in the last 1 week, and is up 59.54% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 10.84% and the 50-Day Moving Average is 22.6%.The 200 Day SMA reached 58.84%
Northwest Biotherapeutics (NASDAQ:NWBO): The stock opened in the green at $0.5577 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $0.58 and a low of $0.53 for the day. The stock did not find buyers even at the lows and closed at $0.5426 recording a loss of -2.22%. 723,588 shares exchanged hands during the trading day. The stock had closed at $0.5426 in the previous days trading.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. The Companys platform technology, DCVax, uses activated dendritic cells to mobilize a patients own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells. DCVax is designed to target a set of biomarkers on the patients tumor. DCVax product lines are made from the patients own dendritic cells, which are freshly isolated, and matured and activated. The Companys DCVax product lines include DCVax-L, DCVax-Direct and DCVax-Prostate. DCVax-L is made with cancer antigens from tumor lysate. DCVax-Direct incorporates a set of tumor antigens in situ. DCVax-Prostate product line is developed based on the antigen, PSMA (Prostate Specific Membrane Antigen), which is found on all late stage prostate cancers.